Tsujikawa, Tetsuya Asahi, Satoko Oh, Myungmi Sato, Yoshitaka Narita, Norihiko Makino, Akira Mori, Tetsuya Kiyono, Yasushi Tsuchida, Tatsuro Kimura, Hirohiko Fujieda, Shigeharu Okazawa, Hidehiko Kaplan-Meier curves of progression-free survival (PFS) for <sup>62</sup>Cu-ATSM PET (a) and <sup>18</sup>F-FDG PET (b) in patients with HNC. <p>Two groups of high (dotted lines) and low (solid lines) tracer accumulation were determined by each cut-off value of the tumor-to-muscle ratios (TMR<sub>ATSM</sub> and TMR<sub>FDG</sub>). TMR<sub>ATSM</sub>, one of the intensity-based redox parameters, showed a significant difference in PFS between two groups (<i>p</i> = 0.03), whereas TMR<sub>FDG</sub>, one of the intensity-based metabolic parameters, did not (<i>p</i> = 0.15). The three-year PFS rate was 74% for patients with lower accumulation tumors (TMR<sub>ATSM</sub> ≤ 3.2) and 29% for those with over-reductive tumors (TMR<sub>ATSM</sub> > 3.2).</p> 18 F-FDG;threshold;TMR ATSM;SUV ATSM;ROC analysis;RTV;CSS;18 F-FDG PET scans;PSF;62 Cu-ATSM PET;18 F-FDG PET;62 Cu-ATSM;Tumor Redox Status;HNC patient outcomes;TLR;TLG;tumor-to-muscle activity concentration ratios;62 Cu-ATSM PET Purpose Tumor redox;MTV;II;PFS;Conclusion Tumor redox parameters;pretreatment 62 Cu-ATSM 2016-05-17
    https://plos.figshare.com/articles/figure/Kaplan-Meier_curves_of_progression-free_survival_PFS_for_sup_62_sup_Cu-ATSM_PET_a_and_sup_18_sup_F-FDG_PET_b_in_patients_with_HNC_/3939063
10.1371/journal.pone.0155635.g003